Introduction {#S0001}
============

Nonsyndromic hearing loss (NSHL) is one of the most common congenital impairments and a genetically extremely heterogeneous disease.[@CIT0001],[@CIT0002] More than 70% of hereditary deafness is nonsyndromic.[@CIT0003] Recent studies have shown that the frequency of hearing loss in Iran was estimated to be two to three times higher compared with other populations of the world.[@CIT0004] As it is considered a potential problem in developing countries, early diagnosis might be highly recommended.[@CIT0005] Consanguineous marriage is prevalent in Iran, and it has been shown that 61.54% of parents with deaf children experienced consanguineous marriage.[@CIT0006] The prevalence of bilateral sensory deafness was 62.90% in seven cities in Iran. Consanguineous marriages are associated with a higher incidence of sensorineural deafness.[@CIT0007],[@CIT0008] Genetic factors play a key role in nonsyndromic hearing impairment (NSHI) and more than 140 genes have been identified to be engaged in deafness.[@CIT0009] It has been clearly shown that different loci might be responsible for deafness. Genetic heterogeneity of deafness might be transferred either autosomal recessive (AR) loci or by engagement of several loci which results in hearing loss.[@CIT0010],[@CIT0011]

At least 140 genes[@CIT0009] and 150 loci have been discovered to play key roles in deafness; 58 loci for autosomal dominant (AD) genes, 87 loci for autosomal recessive genes, and six loci for X-linked genes.[@CIT0012] Mutations in the *MARVELD2* gene which may lead to NSHL, autosomal recessive inheritance, is at the *DFNB49* locus.[@CIT0001],[@CIT0013] *MARVELD2* encodes tricellulin and is located on chromosome 5q13.2.[@CIT0001] Tricellulin is a tricellulin tight-junction (tTJ) protein in the epithelial cells. The inner ear epithelial cells has several tight junction proteins.[@CIT0005],[@CIT0014] Due to the presence of many ethnic groups and the high frequency of consanguineous marriages, the Iranian population is a valuable genetic resource to study NSHL with autosomal recessive inheritance.[@CIT0005]

In the present study, we reported a case of nonsyndromic hearing loss with a previously reported rare mutation in the *MARVELD2* gene which was evaluated by Next Generation Sequencing (NGS).

Materials and Methods {#S0002}
=====================

Case Presentation {#S0002-S2001}
-----------------

A 21-year-old Iranian woman with deafness was referred to the Jordan Medical and Genetics lab for premarital genetic counseling with an unrelated affected man ([Figure 1](#F0001){ref-type="fig"}). Her parents had a consanguineous marriage with no deafness, but her brother was affected with NSHL.Figure 1Pedigree of two families with nonsyndromic hearing loss (autosomal recessive pattern). Filled symbols represent deafness individuals. Clear symbols represent no-deafness individuals. The arrow shows Proband. Dialognal line indicates deceased mal and deseased female.

A second family is a 23-year-old man with deafness, whose parents did not have any sensorial problems, but his step-brother also suffered from deafness. All audio-metric parameters confirmed NSHL in all mentioned cases.

We confirm that all participants gave informed consent with the genetic examination as they were referred to the genetic lab for genetic consultation. Also we confirm that all participants provided written informed consent to have their case details, and any accompanying images, published. Ethical approval was not required.

Investigations {#S0002-S2002}
--------------

A peripheral blood sample was taken from this case. Extracted DNA was sent to one of the companies which are service providers for next generation sequencing and have extended this portfolio by using various leading NGS sequencing technologies. The quality and quantity of each sample was defined by various and suitable methods such as agarose gel analysis, Qubit^®^ Fluorometer, NanoDrop, and Agilent 2100 Bioanalyzer. For this patient, whole exome sequencing (WES), to access the majority of susceptible variants genes, was ordered and performed with an Illumina HiSeq 2500 machine (with SureSelect version6 kit) for ultra-deep sequencing with huge data output. After receiving row data as a fastq, FASTQC software was used for evaluation quality control analysis of read data by the company. The bioinformatics pipeline included Mapping of reads to human genome reference sequence using BWA-MEM, before accurate and annotated insertions-deletions (InDels) and single nucleotide polymorphisms (SNP) detection reports in Variant Calling Format (VCF) format. So SNP and InDel detection, based on the mapping results (VCF format) and annotation of all variants, was compared to known SNP lists (e.g. *dbSNP, Clinvar*), Using an online genome browser for interactive visualization of read mapping and variants, target coverage statistics were prepared for our Laboratory to analyze. After the data was received and analyzed, Sanger sequencing was used due to segregation in her family for evaluating founded variants. Peripheral blood samples were taken from related individuals and segregation analysis with Sanger sequencing was performed to confirm variants for all mentioned persons; II-5, III-2, III-5, III-6, III-8 ([Figure 1](#F0001){ref-type="fig"}).

Primer pairs were used to amplify the mentioned mutation (c.1331+1G\>A) in the *MARVELD2* gene. The sequence of designed primers was as follows: 5ʹ-CACCTGATCTTCTTCCTC-3ʹ as a forward primer and 5ʹ-GGGAAATCAGCTTATCTTAT-3ʹ as a reverse primer.

Results {#S0003}
=======

We achieved annotated files from the European company (Testing and Laboratory Services) with one branch in India. The annotated file which had been sent was reported in two sheets. One of them was for SNPs and the other for InDels. According to the articles, two protocols were suggested to analyze in these cases. Data were sorted by a panel of deafness genes. The generated data was analyzed with the most well known pathogenic Nonsyndromic Hearing Loss (NSHL) genes; *ABHD12*, *ACTG1*, *MSRB3*, *CCDC50*, *CEACAM16*, *CIB2*, *PCDH15*, *COL4A5*, *DFNA5*, *DFNB59*, *SLC17A8*, *EYA1*, *FGF3*, *FOXC1*, *TMPRSS3*, *GPSM2*, *GRXCR1*, *HGF*, *GJB2*, *KCNQ4*, *LOXHD1*, *MARVELD2*, *KCNE1*, *MYO1A*, *MYO6*, *OTOA*, *MYH14*, *RDX*, *SALL1*, *SERPINB6*, *PITX2*, *SMPX*, *TIMM8A*, *TMC1*, *SLC26A4*, *USH1G*, *WFS1*, *ADGRV1*, *TPRN*, *CDH23*, *ABHD5*, *CISD2*, *BSND*, *CRYM*, *CHD7*, *DIABLO*, *COCH*, *EYA4*, *DFNB31*, *FOXI1*, *DSPP*, *GRHL2*, *FGFR3*, *HSD17B4*, *GJB3*, *LHFPL5*, *HARS2*, *MASP1*, *KCNJ10*, *MYO3A*, *LRTOMT*, *OTOF*, *MYH9*, *RPS6KA3*, *MYO7A*, *ARSB*, *POU3F4*, *TECTA*, *SALL4*, *CLDN14*, *SLC26A5*, *USH2A*, *TJP2*, *DIAPH1*, *TRIOBP*, *KCNQ1*, *WHRN*, *GIPC3*, *BTD*, *MYO15A*, *ATP6V1B1*, *ILDR1*, *COL11A2*, *PRPS1*, *CLRN1*, *SIX1*, *ESRRB*, *SLC29A3*, *DNMT1*, *TMIE*, *GJB6*, *USH1C*.

Some variants were filtered according to their functions (exonic/non-exonic). Exonic and splicing sites were selected and Synonymous were deleted. To have a wide evaluation and prevent data missing, we filtered frequencies of variants based on 1000 Genome \<0.05 in spite of the fact that \<0.01 should have been used. The data were analyzed and allele coverage, allele frequency, allele ratio, variant impact, and clinical significance were calculated. Data were checked by various databases including dbSNP, ClinVar, and also predictive databases such as SIFT, PolyPhen, MutationTaster, FATHMM, CADD, and Varsome scores. We should add that the predictive data defined was based on quality (etc. deleterious, non-deleterious, polymorphism, benign) and we could assess according to the quality.

The results analysis revealed a very rare mutation (*c.1331+1G\>A; rs762352115*) in a splice donor site in the *MARVELD2* gene. According to the bioinformatics analysis and annotation with databases, this variant was predicted as pathogenic with related MAF=0.00002. This mutation is reported for the first time in one Iranian family ([Table 1](#T0001){ref-type="table"}).Table 1All Changes in the Case Which Were Revealed by Next Generation SequencingGenesDNA ChangeProtein ChangeZygosityAssociation Disease & InheritanceClassification*MYO7A*NM_001127180:c.G2489Ap.R830HHeterozygousDeafness (AR, AD), Usher syndrome. Type1B(AR)(symptoms: deafness)VOUS*MARVELD2*NM_001038603.2:c1331+1G\>ASplicingHomozygousDeafness (AR)Pathogenic*DSPP*NM_014208:c.G727Ap.D243NHeterozygousDeafness with dentinogenesis (AD), dentin dysplasia, type2 (AD), dentinogenesis imperfect, shields type2 (AD), Dentinogenesis imperfect, shields type3 (AD)Benign*USH2A*NM_206933:c.C3742Ap.P1248THeterozygousUsher syndrome, type2A (with deafness symptoms) (AR)NA*DSPP*NM_014208:c.2018_2019insTAGCAGTGACAGCAGCAGp.D673del insDSSDSSSHeterozygousDeafness with dentinogenesis (AD), dentin dysplasia, type2 (AD), dentinogenesis imperfect, shields type2 (AD), dentinogenesis imperfect, shields type3 (AD)NA nonframeshift insertion*DSPP*NM_014208:c.3055_3072delp.1019_1024delHomozygousDeafness with dentinogenesis (AD), dentin dysplasia, type2 (AD), dentinogenesis imperfect, shields type2 (AD), dentinogenesis imperfect, shields type3 (AD)NA nonframeshift insertion*FOXC1*NM_001453:c.1337_1338insCGGp.H446del insHGHeterozygousAxenfeld-Rieger syndrome, type3 (with deafness symptoms) (AD)NA nonframeshift insertion

The proband; who is indicated in the pedigree (*III-6*), and her brother (*III-8*), were homozygote for mentioned mutation (*c.1331+1G\>A*). Her mother, who has a consanguine marriage (*II-5*), was heterozygote for this variant. Other deaf patients from the second family (*III-2 and III-5*) were homo-normal about the mentioned mutation ([Figures 1](#F0001){ref-type="fig"} and [2](#F0002){ref-type="fig"}). The Sanger results are shown in [Figure 2](#F0002){ref-type="fig"}.Figure 2The results of Sanger sequencing of *MARVELD2* gene mutation. Sequence analysis shows homo-mutant (**A**), hetero-mutant (**B**), and homo-normal (**C**) individuals of families. The splice-site mutation (c. *1331 + 1G \> A)* was found in the case and her family.

The segregation screening revealed that the mentioned mutation (*c.1331+1G\>A*) was seen only in the case (*III-6*) and two members of her family; (*II-5*) as a heterozygote and (*III-8*) who was affected as well.

Discussion {#S0004}
==========

Nonsyndromic hearing loss is a common sensorineural disorder.[@CIT0015] More than 140 genes are known to cause hearing loss.[@CIT0009] NSHL is genetically heterogeneous, but in almost all cases has autosomal recessive inheritance.[@CIT0013] The *MARVELD2* gene is an integral membrane protein, which contains seven exons and 558 amino acids.[@CIT0005],[@CIT0011] The human *MARVELD2* gene at the *DFNB49* locus, which has been shown to cause NSHL in different studies, is located on chromosome 5q13.2 (*Chromosome 5: 68,710,939--68,740,157*).[@CIT0005],[@CIT0016]

Tight junctions (TJ) are composed of networks and many different proteins, and prevent leakage of transported solutes in epithelial cells.[@CIT0017] One of the integral membrane proteins; *MARVELD2* or Tricellulin (TRIC), is concentrated in TJ strands of inner-ear epithelia.[@CIT0018]

TRIC is necessary to form the epithelial barrier. Suppression of mouse TRIC showed disorganized tricellular contacts.[@CIT0017] Homozygous mutation in TRIC (*MARVELD2; 610,572*) causes deafness-49 with an autosomal recessive pattern (*DFNB49*).[@CIT0019]

We evaluated a patient with NSHL by a panel of deafness with NGS and found a very rare mutation in the *MARVELD2* gene (*c.1331+1G\>A*). There was just one previous population in the world (Pakistani families) that had reported this mutation related to NSHL, and there were no other reports worldwide. Some other pathogenic variants of the *MARVELD2* gene have been reported in different countries ([Table 2](#T0002){ref-type="table"}).[@CIT0003],[@CIT0005],[@CIT0013],[@CIT0015],[@CIT0018],[@CIT0020],[@CIT0021],[@CIT0022]Table 2All Variants of *MARVELD~2~* Gene Which Previously Reported Were Caused of Hearing LossMutationOrigin of FamilyReferencec.1331+2T\>CPakistani, Czech Roma, Slovak Roma, Hungarian RomaSaima Riazuddin et al, 2006[@CIT0018]Gowri Nayak et al, 2015[@CIT0020]ˇSafka Broˇzkov et al, 2012[@CIT0013]Ivica Mašindová et al, 2015[@CIT0021]c.1331--1G\>APakistaniSaima Riazuddin et al, 2006[@CIT0018]c.1331+2delTGAGPakistaniSaima Riazuddin et al, 2006[@CIT0018]c.1498C\>TPakistaniSaima Riazuddin et al, 2006[@CIT0018]Exon4_5 deletionPakistaniGowri Nayak et al, 2015[@CIT0020]c.1543delAIranianMojgan Babanejad et al, 2012[@CIT0015]c.1331+1G\>APakistaniMuhammad S. Chishti et al, 2008[@CIT0003]This reportc.1555delinsAAIranianAfsaneh Taghipour-Sheshdeh et al, 2018[@CIT0005]c.949C\>GChineseJing Zheng et al, 2019[@CIT0022]c.772G\>AChineseJing Zheng et al, 2019[@CIT0022]c.730G\>AChineseJing Zheng et al, 2019[@CIT0022]c.1006C\>TChineseJing Zheng et al, 2019[@CIT0022]

In Pakistani families, the prevalence of NSHL, with autosomal recessive pattern, due to *MARVELD2* mutations, is about 1.06%.[@CIT0019] This variant, the same as in a previously mentioned report, was considered to be pathogenic variant (MAF=0.00002) in this Iranian family, as had been reported previously in one Pakistani family in 2008.[@CIT0003] The prevalence of this variation is not clear in Iranian families due to no evaluated data in our population.

We imagine that it could be some connection between this Iranian family and the Pakistani region due to the same mutation appearing in these two populations, maybe there is a common old ancestor creating a possible origin of this mutation.[@CIT0023] So further large prospective studies are required to confirm, and we recommend more investigations in these populations. This is the first report of this mutation in the Iranian family with NSHL and the second report worldwide. These findings suggest that the *MARVELD2* gene should be considered in Iranian patients affected with NSHL.

Conclusion {#S0005}
==========

The segregation and data bases annotations revealed that the *MARVELD2* gene *c.1331+1G\>A* variant is probably a pathogenic mutation that can cause NSHL which shows autosomal recessive inheritance pattern.
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AD, Autosomal Dominant; AR, Autosomal Recessive; BWA, Burrows--Wheeler Aligner; CADD, Combined Annotation Dependent Depletion; ClinVar, Clinical Variant; dbSNP, single Nucleotide Polymorphism Database; DFNB, Deafness, Autosomal Recessive; FATHMM, Functional Analysis through Hidden Markov Models; InDel, Insertion-Deletion; MEM, Maximum Exact Matches; NGS, Next Generation Sequencing; NSHL, Nonsyndromic Hearing Loss; PolyPhen, Polymorphism Phenotyping; rs, refSNP; SIFT, Sorting Intolerant From Tolerant; SNP, Single Nucleotide Polymorphism; tTJ, tricellulin Tight-Junction; VCF, Variant Calling Format; WES, Whole Exome Sequencing; □, male; ○, female; ●, Affected female; ■, Affected male; □, Deceased male; ○, Deceased female; ═, Consanguineous Marriage; ──, Nonconsanguineous Marriage.
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